Bone mineral density in normal and asthmatic children

Kirk A. Kinberg, Russell J. Hopp, Rus E. Biven, John Christopher G. Gallagher

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Background: The largest increase in bone mass occurs during childhood and adolescence. A subnormal bone mass is associated with increased risk of fracture. Bone mass is influenced by height, age, race, exercise, and stage of puberty. It is adversely affected by chronic disease states and corticosteroid use. We performed a cross-sectional study of bone density in children with moderate to severe asthma who were treated with inhaled corticosteroids, inhaled cromolyn, oral corticosteroids, or a combination of these, and we compared them with normal children. Methods: A cross-sectional study of bone density, measured either by dual-photon or dual-energy absorptiometry, was performed on 97 normal white and 30 asthmatic white children, aged 5 to 18. Average daily calcium intake, height, weight, and Tanner stage were determined. The total daily and lifetime doses of inhaled corticosteroids in children with asthma were calculated. T tests, multiple regression, chi square analysis, and analysis of covariance were performed. Results: No significant difference in bone density was demonstrated between children with asthma and normal control subjects. No measure (including calcium intake, Tanner stage, daily or lifetime inhaled corticosteroid dose, or duration of illness), except for height and age, provided a significant contribution to the explanation of bone density in children with asthma. Conclusion: Children and adolescents with moderate to severe asthma, including those treated with inhaled corticosteroids, do not appear to have adversely affected bone mass. There was, however, the possibility of a type II error in this study because of the sample size.

Original languageEnglish
Pages (from-to)490-497
Number of pages8
JournalJournal of Allergy and Clinical Immunology
Volume94
Issue number3 PART 1
DOIs
StatePublished - 1994

Fingerprint

Bone Density
Adrenal Cortex Hormones
Asthma
Bone and Bones
Cross-Sectional Studies
Calcium
Cromolyn Sodium
Puberty
Photons
Sample Size
Chronic Disease
Exercise
Weights and Measures

All Science Journal Classification (ASJC) codes

  • Immunology
  • Immunology and Allergy

Cite this

Bone mineral density in normal and asthmatic children. / Kinberg, Kirk A.; Hopp, Russell J.; Biven, Rus E.; Gallagher, John Christopher G.

In: Journal of Allergy and Clinical Immunology, Vol. 94, No. 3 PART 1, 1994, p. 490-497.

Research output: Contribution to journalArticle

Kinberg, Kirk A. ; Hopp, Russell J. ; Biven, Rus E. ; Gallagher, John Christopher G. / Bone mineral density in normal and asthmatic children. In: Journal of Allergy and Clinical Immunology. 1994 ; Vol. 94, No. 3 PART 1. pp. 490-497.
@article{aef30fce57724dc18202ce252be8f12f,
title = "Bone mineral density in normal and asthmatic children",
abstract = "Background: The largest increase in bone mass occurs during childhood and adolescence. A subnormal bone mass is associated with increased risk of fracture. Bone mass is influenced by height, age, race, exercise, and stage of puberty. It is adversely affected by chronic disease states and corticosteroid use. We performed a cross-sectional study of bone density in children with moderate to severe asthma who were treated with inhaled corticosteroids, inhaled cromolyn, oral corticosteroids, or a combination of these, and we compared them with normal children. Methods: A cross-sectional study of bone density, measured either by dual-photon or dual-energy absorptiometry, was performed on 97 normal white and 30 asthmatic white children, aged 5 to 18. Average daily calcium intake, height, weight, and Tanner stage were determined. The total daily and lifetime doses of inhaled corticosteroids in children with asthma were calculated. T tests, multiple regression, chi square analysis, and analysis of covariance were performed. Results: No significant difference in bone density was demonstrated between children with asthma and normal control subjects. No measure (including calcium intake, Tanner stage, daily or lifetime inhaled corticosteroid dose, or duration of illness), except for height and age, provided a significant contribution to the explanation of bone density in children with asthma. Conclusion: Children and adolescents with moderate to severe asthma, including those treated with inhaled corticosteroids, do not appear to have adversely affected bone mass. There was, however, the possibility of a type II error in this study because of the sample size.",
author = "Kinberg, {Kirk A.} and Hopp, {Russell J.} and Biven, {Rus E.} and Gallagher, {John Christopher G.}",
year = "1994",
doi = "10.1016/0091-6749(94)90205-4",
language = "English",
volume = "94",
pages = "490--497",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "3 PART 1",

}

TY - JOUR

T1 - Bone mineral density in normal and asthmatic children

AU - Kinberg, Kirk A.

AU - Hopp, Russell J.

AU - Biven, Rus E.

AU - Gallagher, John Christopher G.

PY - 1994

Y1 - 1994

N2 - Background: The largest increase in bone mass occurs during childhood and adolescence. A subnormal bone mass is associated with increased risk of fracture. Bone mass is influenced by height, age, race, exercise, and stage of puberty. It is adversely affected by chronic disease states and corticosteroid use. We performed a cross-sectional study of bone density in children with moderate to severe asthma who were treated with inhaled corticosteroids, inhaled cromolyn, oral corticosteroids, or a combination of these, and we compared them with normal children. Methods: A cross-sectional study of bone density, measured either by dual-photon or dual-energy absorptiometry, was performed on 97 normal white and 30 asthmatic white children, aged 5 to 18. Average daily calcium intake, height, weight, and Tanner stage were determined. The total daily and lifetime doses of inhaled corticosteroids in children with asthma were calculated. T tests, multiple regression, chi square analysis, and analysis of covariance were performed. Results: No significant difference in bone density was demonstrated between children with asthma and normal control subjects. No measure (including calcium intake, Tanner stage, daily or lifetime inhaled corticosteroid dose, or duration of illness), except for height and age, provided a significant contribution to the explanation of bone density in children with asthma. Conclusion: Children and adolescents with moderate to severe asthma, including those treated with inhaled corticosteroids, do not appear to have adversely affected bone mass. There was, however, the possibility of a type II error in this study because of the sample size.

AB - Background: The largest increase in bone mass occurs during childhood and adolescence. A subnormal bone mass is associated with increased risk of fracture. Bone mass is influenced by height, age, race, exercise, and stage of puberty. It is adversely affected by chronic disease states and corticosteroid use. We performed a cross-sectional study of bone density in children with moderate to severe asthma who were treated with inhaled corticosteroids, inhaled cromolyn, oral corticosteroids, or a combination of these, and we compared them with normal children. Methods: A cross-sectional study of bone density, measured either by dual-photon or dual-energy absorptiometry, was performed on 97 normal white and 30 asthmatic white children, aged 5 to 18. Average daily calcium intake, height, weight, and Tanner stage were determined. The total daily and lifetime doses of inhaled corticosteroids in children with asthma were calculated. T tests, multiple regression, chi square analysis, and analysis of covariance were performed. Results: No significant difference in bone density was demonstrated between children with asthma and normal control subjects. No measure (including calcium intake, Tanner stage, daily or lifetime inhaled corticosteroid dose, or duration of illness), except for height and age, provided a significant contribution to the explanation of bone density in children with asthma. Conclusion: Children and adolescents with moderate to severe asthma, including those treated with inhaled corticosteroids, do not appear to have adversely affected bone mass. There was, however, the possibility of a type II error in this study because of the sample size.

UR - http://www.scopus.com/inward/record.url?scp=0028050290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028050290&partnerID=8YFLogxK

U2 - 10.1016/0091-6749(94)90205-4

DO - 10.1016/0091-6749(94)90205-4

M3 - Article

VL - 94

SP - 490

EP - 497

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 3 PART 1

ER -